Clinical Scorecard: Comparative Analysis of Consolidative and Salvage Stereotactic Ablative Radiotherapy for Primary Lung Tumors in Stage IV Non-Small Cell Lung Cancer
At a Glance
Category
Detail
Condition
Stage IV Non-Small Cell Lung Cancer (NSCLC)
Key Mechanisms
Stereotactic Ablative Radiotherapy (SABR) delivered as either consolidative or salvage therapy.
Target Population
Patients with stage IV NSCLC receiving SABR to primary lung tumors.
Care Setting
Department of Radiation Oncology, Chongqing University Cancer Hospital.
Key Highlights
Consolidative and salvage SABR showed comparable local progression-free survival (LPFS), distant metastasis-free survival (DMFS), and overall survival (OS).
EGFR/ALK mutations were associated with improved LPFS, DMFS, and OS.
Grade ≥2 radiation pneumonitis occurred in 12.2% of patients with no significant difference between groups.
SABR timing did not independently dictate long-term oncologic outcomes.
Future trials should prioritize composite endpoints including toxicity and quality of life.
Guideline-Based Recommendations
Diagnosis
Histologically confirmed stage IV NSCLC per AJCC Staging System.
Management
First-line systemic therapy in accordance with clinical guidelines.
Consolidative SABR before disease progression; salvage SABR for oligo-progression.
Monitoring & Follow-up
Follow-up with laboratory tests and imaging every 6–8 weeks, then every 3–6 months.
Risks
Potential for grade ≥2 radiation pneumonitis.
Patient & Prescribing Data
90 patients with stage IV NSCLC.
Consolidative SABR (n=64) and salvage SABR (n=26) were analyzed for efficacy and safety.
Clinical Best Practices
Consider tumor anatomy and anticipated toxicity when deciding between consolidative and salvage SABR.
Utilize multidisciplinary team input for local therapy to metastatic lesions.
